Drug Profile
Paridiprubart - Edesa Biotech
Alternative Names: EB 05; EB-07; NI-0101Latest Information Update: 11 Apr 2024
Price :
$50
*
At a glance
- Originator NovImmune SA
- Developer Edesa Biotech; Light Chain Bioscience
- Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Toll-like receptor 4 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III SARS-CoV-2 acute respiratory disease
- Phase II Idiopathic pulmonary fibrosis; Interstitial lung diseases; Rheumatoid arthritis
Most Recent Events
- 11 Apr 2024 Phase-II clinical trials in Idiopathic pulmonary fibrosis (IV) (Edesa Biotech pipeline, April 2024)
- 11 Apr 2024 Phase-II clinical trials in Interstitial lung diseases (IV) before April 2024 (Edesa Biotech pipeline, April 2024)
- 10 Jul 2023 Edesa Biotech and US FDA agrees on primary endpoint for phase III trial in Adult respiratory distress syndrome